Pancreatic Cancer Research

ResearcherUniversité Libre de BruxellesActive in the last 2 years

Julie Navez

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5362-8764; OpenAlex author ID A5004144692. Sources: OpenAlex.

Their work

Papers
18 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
70
Papers, trials and grants by year

2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 5 papers · 2024: 4 papers · 2025: 2 papers · 2026: 3 papers

Papers 18

  1. International survey on neoadjuvant treatments in anatomically resectable pancreatic adenocarcinoma (INSPIRA): a real-life snapshot. Co-author DOI 10.1016/j.suronc.2026.102580↗
  2. Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-dose stereotactic body radiotherapy. Co-author DOI 10.1038/s41416-025-03274-0↗
  3. Futility in adenosquamous pancreatic cancer. Co-author DOI 10.1186/s12957-026-04351-1↗
  4. Glycation Stress–Driven Transcriptomic Signature Predicts Survival Benefit from Adjuvant Gemcitabine in Resectable Pancreatic Cancer Co-author DOI 10.1101/2025.07.07.663493↗
  5. Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter T… Co-author DOI 10.1245/s10434-024-16735-2↗
  6. Impact of the radiological morphology of the mesopancreas on the outcome after pancreatoduodenectomy for pancreatic ductal adenocarcinoma: retrospective study. Co-author DOI 10.1093/bjsopen/zrae134↗
  7. Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Stereotactic Body Radiotherapy Co-author DOI 10.1101/2024.04.30.591890↗
  8. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma or a Metaphor for Heterogeneity: From Single-Cell Analysis to Whole-Body Imaging. Co-author DOI 10.3390/biomedicines12030591↗
  9. Total Neoadjuvant Therapy in Localized Pancreatic Cancer: Is More Better? Co-author DOI 10.3390/cancers16132423↗
  10. Neoadjuvant chemotherapy associated with isotoxic high-dose stereotactic body radiotherapy does not increase postoperative complications after pancreaticoduode… Co-author DOI 10.1002/jso.27252↗
  11. Peritoneal patch in vascular reconstruction during pancreaticoduodenectomy for pancreatic cancer: a single Centre experience. Last author DOI 10.1080/00015458.2021.1979173↗
  12. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline rese… First author DOI 10.1186/s12885-023-11327-x↗
  13. Combination, Modulation and Interplay of Modern Radiotherapy with the Tumor Microenvironment and Targeted Therapies in Pancreatic Cancer: Which Candidates to B… Co-author DOI 10.3390/cancers15030768↗
  14. A Comprehensive Review of the Potential Role of Liquid Biopsy as a Diagnostic, Prognostic, and Predictive Biomarker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells13010003↗
  15. Isotoxic High-Dose Stereotactic Body Radiotherapy (iHD-SBRT) Versus Conventional Chemoradiotherapy for Localized Pancreatic Cancer: A Single Cancer Center Eval… First author DOI 10.3390/cancers14235730↗
  16. Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenoc… Co-author DOI 10.1177/17588359211045860↗
  17. What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact? Co-author DOI 10.1245/s10434-020-09568-2↗
  18. Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard? First author DOI 10.1177/1758835920936093↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christelle Bouchart · 15 shared papers, 2020–2026 · strength 2.76
  2. Jean‐Luc Van Laethem · 14 shared papers, 2020–2026 · strength 2.56
  3. Tatjana Arsenijevic · 7 shared papers, 2023–2026 · strength 1.37
  4. Jean Closset · 8 shared papers, 2020–2024 · strength 1.30
  5. Oier Azurmendi Senar · 6 shared papers, 2023–2026 · strength 1.19
  6. Kosta Stosic · 5 shared papers, 2023–2026 · strength 1.00
  7. Pieter Demetter · 5 shared papers, 2023–2026 · strength 0.95
  8. Maria Antonietta Bali · 5 shared papers, 2021–2024 · strength 0.79
  9. Nicky D’Haene · 4 shared papers, 2023–2026 · strength 0.75
  10. Matthieu Hein · 4 shared papers, 2021–2026 · strength 0.64
  11. Rémy Nicolle · 3 shared papers, 2024–2026 · strength 0.58
  12. Rita Saúde-Conde · 2 shared papers, 2024 · strength 0.50
  13. Léo Mas · 2 shared papers, 2024–2026 · strength 0.38
  14. Shulin Zhao · 2 shared papers, 2024–2026 · strength 0.38
  15. Ilse Rooman · 2 shared papers, 2024–2026 · strength 0.38
  16. Jean‐Baptiste Bachet · 2 shared papers, 2024–2026 · strength 0.38
  17. Marie-Lucie Racu · 2 shared papers, 2023–2024 · strength 0.37
  18. Pietro Addeo · 2 shared papers, 2025–2026 · strength 0.34
  19. Philippe Bachellier · 2 shared papers, 2025–2026 · strength 0.34
  20. Alain Hendlisz · 2 shared papers, 2020–2021 · strength 0.24
  21. Ellis Michiels · 1 shared paper, 2026 · strength 0.22
  22. Jean-Luc Van-Laethem · 1 shared paper, 2025 · strength 0.20
  23. Thierry Conroy · 1 shared paper, 2025 · strength 0.20
  24. Akeila Bellahcène · 1 shared paper, 2025 · strength 0.20
  25. Rebekah Crake · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.